Northern Trust Corp Boosts Position in Oxford Immunotec Global PLC (NASDAQ:OXFD)

Northern Trust Corp boosted its stake in shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) by 20.0% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 243,961 shares of the company’s stock after purchasing an additional 40,637 shares during the period. Northern Trust Corp owned approximately 1.06% of Oxford Immunotec Global worth $4,104,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in OXFD. Renaissance Technologies LLC grew its position in Oxford Immunotec Global by 97.8% during the 1st quarter. Renaissance Technologies LLC now owns 363,300 shares of the company’s stock worth $5,628,000 after purchasing an additional 179,600 shares during the period. Penn Capital Management Co. Inc. grew its position in Oxford Immunotec Global by 51.6% during the 2nd quarter. Penn Capital Management Co. Inc. now owns 179,415 shares of the company’s stock worth $3,018,000 after purchasing an additional 61,080 shares during the period. Essex Investment Management Co. LLC grew its position in Oxford Immunotec Global by 27.7% during the 2nd quarter. Essex Investment Management Co. LLC now owns 141,197 shares of the company’s stock worth $2,375,000 after purchasing an additional 30,637 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Oxford Immunotec Global by 175.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 35,678 shares of the company’s stock worth $553,000 after acquiring an additional 22,704 shares in the last quarter. Finally, Alliancebernstein L.P. purchased a new stake in shares of Oxford Immunotec Global during the 2nd quarter worth about $247,000. 89.35% of the stock is currently owned by institutional investors.

Several equities research analysts have recently issued reports on the stock. Cowen reissued a “buy” rating and set a $19.00 target price on shares of Oxford Immunotec Global in a research note on Thursday, September 28th. BTIG Research assumed coverage on shares of Oxford Immunotec Global in a research note on Thursday, September 28th. They set a “buy” rating and a $21.00 target price on the stock. Zacks Investment Research raised shares of Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. ValuEngine lowered shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research note on Tuesday, October 31st. Finally, Robert W. Baird reissued a “buy” rating and set a $20.00 target price on shares of Oxford Immunotec Global in a research note on Wednesday, November 1st. Two investment analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $19.75.

Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) traded down $0.40 during trading on Wednesday, reaching $14.19. 82,600 shares of the company were exchanged, compared to its average volume of 111,616. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.30 and a current ratio of 4.72. Oxford Immunotec Global PLC has a 1 year low of $12.19 and a 1 year high of $19.51.

In other news, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $13.35, for a total transaction of $40,050.00. Following the completion of the sale, the director now owns 17,778 shares in the company, valued at approximately $237,336.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Peter Wrighton-Smith sold 55,000 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $16.78, for a total transaction of $922,900.00. The disclosure for this sale can be found here. Company insiders own 8.11% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2017/12/06/oxford-immunotec-global-plc-oxfd-stake-increased-by-northern-trust-corp.html.

Oxford Immunotec Global Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Institutional Ownership by Quarter for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply